EUVIMEDEUVIMED entdecken
Crossref

Loss of Methylthioadenosine Phosphorylase (MTAP) Expression: A Potentially Useful Tool for Distinguishing Sarcomatoid Urothelial Carcinoma from Inflammatory Myofibroblastic Tumor

Huili Li, Pedram Argani, John M Gross, Jing Zhu, Aparna Pallavajjala, Alexander S Baras, Tamara L Lotan, Jonathan C Dudley, Andres Matoso, Ezra G Baraban

Modern Pathology · 2026

DOI: 10.1016/j.modpat.2026.100980 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026. Verfasst von Huili Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland. Hauptthemen laut MEDLINE: Purine-Nucleoside Phosphorylase, Biomarkers, Tumor, Neoplasms, Muscle Tissue, Urologic Neoplasms. Die Arbeit nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory myofibroblastic tumor (IMT) and sarcomatoid urothelial carcinoma (SarUC) can have striking histologic overlap but have significantly different prognoses and clinical management paradigms. Loss of methylthioadenosine phosphorylase (MTAP) protein expression by immunohistochemistry (IHC) serves as a useful surrogate for homozygous 9p21 deletion, a recurrent genomic alteration in urothelial carcinoma (UC). We analyzed MTAP expression by IHC in 65 SarUCs and 27 urinary tract IMTs to evaluate its utility in navigating this challenging differential diagnosis. Overall, MTAP loss was significantly more frequent in SarUC (55%) compared with IMT (4%) (P < .0001). Among 46 biphasic SarUCs with independently evaluable epithelial and mesenchymal components, divergent expression patterns were frequent. The most common pattern was retention of MTAP staining in both epithelial and mesenchymal components (19/46; 41% of cases), followed by selective retention of MTAP in the epithelial component and loss in the mesenchymal component (16/46; 35% of cases). MTAP loss was observed in both the epithelial and mesenchymal components in 11 out of 46 (24%) SarUC cases. None of the 46 biphasic SarUC cases showed selective MTAP loss in the epithelial component but retention in the mesenchymal component. MTAP IHC was also particularly valuable in assessing clonal relationships in 2 challenging biphasic cases in which the differential diagnosis included a collision between a noninvasive low-grade papillary UC and an IMT versus a subtle IMT-like SarUC arising in association with an overlying noninvasive low-grade papillary UC. Next-generation sequencing on a subset of cases (n = 11) was useful for confirming 9p deletion in cases with MTAP loss by IHC, and for demonstrating molecular hallmarks of urothelial neoplasia thereby providing additional diagnostic support for morphologically challenging SarUC cases with IMT-like morphology. Therefore, MTAP IHC can be useful in evaluating spindle cell lesions of the urinary tract, as loss is significantly more common in SarUC than in IMT, and enriched in the mesenchymal component of biphasic SarUC. However, MTAP loss can be seen in both entities, and the diagnosis of IMT-like spindle cell tumors in the urinary tract requires careful integration of morphologic, immunohistochemical, and molecular data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purine-Nucleoside PhosphorylaseBiomarkers, TumorNeoplasms, Muscle TissueUrologic NeoplasmsHumansDiagnosis, DifferentialFemaleImmunohistochemistryMaleMiddle AgedAgedAged, 80 and overAdult

Stichwörter der Autor:innen

inflammatory myofibroblastic tumormethylthioadenosine phosphorylasesarcomatoid urothelial carcinoma

Substanzen

Purine-Nucleoside Phosphorylase5'-methylthioadenosine phosphorylaseBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland.
  • Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland; Department of Oncology, Johns Hopkins Hospital, Baltimore, Maryland.
  • Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland; Department of Oncology, Johns Hopkins Hospital, Baltimore, Maryland; Department of Urology, Johns Hopkins Hospital, Baltimore, Maryland.
  • Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland. Electronic address: ebaraba1@jhmi.edu.

Zitieren

APA

Li, H., Argani, P., Gross, J. M., Zhu, J., Pallavajjala, A., Baras, A. S., Lotan, T. L., Dudley, J. C., Matoso, A., & Baraban, E. G. (2026). Loss of Methylthioadenosine Phosphorylase (MTAP) Expression: A Potentially Useful Tool for Distinguishing Sarcomatoid Urothelial Carcinoma from Inflammatory Myofibroblastic Tumor. Modern Pathology. https://doi.org/10.1016/j.modpat.2026.100980

Vancouver

Li H, Argani P, Gross JM, Zhu J, Pallavajjala A, Baras AS, et al. Loss of Methylthioadenosine Phosphorylase (MTAP) Expression: A Potentially Useful Tool for Distinguishing Sarcomatoid Urothelial Carcinoma from Inflammatory Myofibroblastic Tumor. Modern Pathology. 2026. doi:10.1016/j.modpat.2026.100980

BibTeX
@article{Li2026,
  author = {Li, Huili and Argani, Pedram and Gross, John M and Zhu, Jing and Pallavajjala, Aparna and Baras, Alexander S and Lotan, Tamara L and Dudley, Jonathan C and Matoso, Andres and Baraban, Ezra G},
  title = {Loss of Methylthioadenosine Phosphorylase (MTAP) Expression: A Potentially Useful Tool for Distinguishing Sarcomatoid Urothelial Carcinoma from Inflammatory Myofibroblastic Tumor},
  journal = {Modern Pathology},
  year = {2026},
  doi = {10.1016/j.modpat.2026.100980}
}
Kostenlos starten →